JPH01283208A - Beautifying cosmetic - Google Patents
Beautifying cosmeticInfo
- Publication number
- JPH01283208A JPH01283208A JP10975688A JP10975688A JPH01283208A JP H01283208 A JPH01283208 A JP H01283208A JP 10975688 A JP10975688 A JP 10975688A JP 10975688 A JP10975688 A JP 10975688A JP H01283208 A JPH01283208 A JP H01283208A
- Authority
- JP
- Japan
- Prior art keywords
- ascorbic acid
- magnesium
- cosmetic
- acid phosphate
- tocopherol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 28
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 20
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 claims abstract description 17
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 11
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 10
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 9
- 229940046009 vitamin E Drugs 0.000 claims abstract description 9
- 239000011709 vitamin E Substances 0.000 claims abstract description 9
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 9
- 239000002076 α-tocopherol Substances 0.000 claims abstract description 6
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 claims abstract description 6
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 claims abstract description 6
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 4
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims abstract description 4
- 235000004835 α-tocopherol Nutrition 0.000 claims abstract description 4
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 claims abstract description 3
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 claims abstract description 3
- 235000010389 delta-tocopherol Nutrition 0.000 claims abstract description 3
- 229950009883 tocopheryl nicotinate Drugs 0.000 claims abstract description 3
- 239000011590 β-tocopherol Substances 0.000 claims abstract description 3
- 235000007680 β-tocopherol Nutrition 0.000 claims abstract description 3
- 239000002446 δ-tocopherol Substances 0.000 claims abstract description 3
- 235000010382 gamma-tocopherol Nutrition 0.000 claims abstract 2
- 239000002478 γ-tocopherol Substances 0.000 claims abstract 2
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 claims abstract 2
- 230000002087 whitening effect Effects 0.000 claims description 14
- 229960000984 tocofersolan Drugs 0.000 claims description 6
- 229940087168 alpha tocopherol Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 229940042585 tocopherol acetate Drugs 0.000 claims description 3
- 229940066595 beta tocopherol Drugs 0.000 claims description 2
- 208000003351 Melanosis Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 abstract 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 231100000245 skin permeability Toxicity 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229960005070 ascorbic acid Drugs 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 206010014970 Ephelides Diseases 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- -1 fatty acid esters Chemical class 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- IRVNEGRHQKGRGD-WPXUHFOISA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;hexadecanoic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O IRVNEGRHQKGRGD-WPXUHFOISA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- DWKNOLCXIFYNFV-HSZRJFAPSA-N 2-[[(2r)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-n,n,6-trimethylpyridine-4-carboxamide Chemical compound CN(C)C(=O)C1=CC(C)=NC(NC(=O)[C@@H]2N(C(=O)CC2)C2CCN(CC=3C=C(C)C(Cl)=CC=3)CC2)=C1 DWKNOLCXIFYNFV-HSZRJFAPSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229910000401 monomagnesium phosphate Inorganic materials 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920006298 saran Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は新規な皮膚美白化粧料に関する。さらに詳しく
は、Ｌ−アスコルビン酸りん酸マグネシウムとビタミン
Ｅ又はその誘導体を有効成分として含有せしめた、美白
効果の著しく改良された美白化粧料に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a novel skin whitening cosmetic. More specifically, the present invention relates to a whitening cosmetic containing magnesium L-ascorbic acid phosphate and vitamin E or a derivative thereof as active ingredients, and which has a significantly improved whitening effect.
皮膚の日焼けによるしみ、色黒、そばかすの原因として
は、一般にはホルモンの異常や日光からの紫外線の刺激
が原因となって、メラニン色素が形成され、これが皮膚
内に異常沈着するものと考えられている。このような、
しみ、色黒、そばかすの治療、改善に有効な化合物とし
てアスコルビン酸及びアスコルビン酸高級脂肪酸エステ
ルカ用いられている。また、最近Ｌ−アスコルビン酸り
ん酸マグネシウムが単独で用いられている。The causes of sun spots, dark skin, and freckles on the skin are generally thought to be caused by hormonal abnormalities or stimulation by ultraviolet rays from sunlight, which leads to the formation of melanin pigment, which is abnormally deposited within the skin. ing. like this,
Ascorbic acid and ascorbic acid higher fatty acid esters are used as compounds effective in treating and improving age spots, dark skin, and freckles. Furthermore, recently, magnesium L-ascorbic acid phosphate has been used alone.
アスコルビン酸は、熱や光に対して極めて不安定で酸化
され易い性質を有し、特に水系の化粧料中においては分
解し、変臭、着色を招き易い問題がある。Ascorbic acid has the property of being extremely unstable to heat and light and easily oxidized, and particularly in water-based cosmetics, it tends to decompose, causing odor and discoloration.
また、アスコルビン酸高級脂肪酸エステルは安定性は改
善されているが、油溶性となってしまう為、水系の化粧
料に配合しずらく、美白効果も弱い問題がある。Furthermore, although the stability of ascorbic acid higher fatty acid esters has been improved, since they are oil-soluble, they are difficult to incorporate into water-based cosmetics and have a weak whitening effect.
最近、Ｌ−アスコルビン酸りん酸マグネシウムが美白効
果に優れ化粧品に配合されている。しかし、本品は皮膚
透過性が充分でなく、美白効果を得る為には配合料を多
くしなければならない問題がある。Recently, magnesium L-ascorbic acid phosphate has been incorporated into cosmetics due to its excellent whitening effect. However, this product has a problem in that it does not have sufficient skin permeability and requires a large amount of ingredients in order to obtain a whitening effect.
本発明者らは、このような事情に鑑み、鋭意研究を重ね
た結果、Ｌ−アスコルビン酸りん酸マグネシウムとビタ
ミンＥ又はその誘導体を併用することにより、皮膚透過
性に優れ、しみ、色黒、そばかすを著しく改善させ、美
白効果が相乗的に増大し、さらに安定性に優れているこ
とを見いだし、本発明を完成するに至った。In view of these circumstances, the present inventors have conducted intensive research and found that by using magnesium L-ascorbic acid phosphate in combination with vitamin E or its derivatives, it has excellent skin permeability and can reduce age spots, dark skin, and The present inventors have discovered that it significantly improves freckles, synergistically increases the whitening effect, and has excellent stability, leading to the completion of the present invention.
すなわち、本発明は、Ｌ−アスコルビン酸りん酸マグネ
シウムとビタミンＥ又はその誘導体の一種又は二種以上
とを含有することを特徴とする化粧料である。That is, the present invention is a cosmetic material containing magnesium L-ascorbic acid phosphate and one or more kinds of vitamin E or its derivatives.
本発明に使用するＬ−アスコルビン酸りん酸マグネシウ
ムの配合料は、化粧料全体中の０．００１〜１０．０重
量％、好ましくは０．０１〜５゜０重量％である。０．
００１重量％以下であると本発明で言う効果が充分に発
揮されず好ましくない。また、１０．０重量％以上の配
合も可能であるが、効果の顕著な増加も認められず、経
済的でない。The amount of magnesium L-ascorbic acid phosphate used in the present invention is 0.001 to 10.0% by weight, preferably 0.01 to 5.0% by weight, based on the total cosmetic composition. 0.
If it is less than 0.001% by weight, the effects referred to in the present invention will not be sufficiently exhibited, which is not preferable. It is also possible to incorporate 10.0% by weight or more, but no significant increase in effectiveness is observed and this is not economical.
本発明に使用するビタミンＥ又はその誘導体としては、
例えばα−トコフェロール、β−トコフェロール、γ−
トコフェロール、δ−トコフェロール、酢酸トコフエロ
ーノｋ又はニコチン酸トコフェロール等が挙げられる。Vitamin E or its derivatives used in the present invention include:
For example, α-tocopherol, β-tocopherol, γ-
Examples include tocopherol, δ-tocopherol, tocopherol acetate, and tocopherol nicotinate.
その配合料としては、化粧料全体中の０．０００５〜５
，０重量％、好ましくは０，００１〜２．０重量％であ
る。０゜０００５重量％以下であると本発明で言う相乗
効果が得られない。５．０重量％以上の配合は、効果の
顕著な増加も認められず、経済的でない。Its compounding ingredient is 0.0005 to 5 in the entire cosmetic.
,0% by weight, preferably 0,001 to 2.0% by weight. If it is less than 0°0005% by weight, the synergistic effect referred to in the present invention cannot be obtained. If the amount is 5.0% by weight or more, no significant increase in effectiveness is observed and it is not economical.
なお、本発明の化粧料は通常の製造方法に従って実施す
る事かできる。Incidentally, the cosmetic composition of the present invention can be produced according to a conventional manufacturing method.
本発明の化粧料は前記の必須成分に加えて必要に応じて
本発明の効果を損なわない範囲内で、化粧品一般に用い
られる各種成分すなわち油脂類、ロウ類、炭化水素類、
脂肪酸類、アルコール類、合成エステル類、界面活性剤
、保湿剤、増粘剤゛、無機物、香料、薬剤、水等を配合
することができる。In addition to the above-mentioned essential ingredients, the cosmetic of the present invention may contain various ingredients commonly used in cosmetics, such as oils and fats, waxes, hydrocarbons, etc., if necessary, within a range that does not impair the effects of the present invention.
Fatty acids, alcohols, synthetic esters, surfactants, humectants, thickeners, inorganic substances, fragrances, drugs, water, etc. can be blended.
次ぎに、実施例をあげて本発明をさらに詳細に説明する
が、本発明はこれにより限定されるものではない。Next, the present invention will be explained in more detail with reference to Examples, but the present invention is not limited thereto.
実施例−１化粧水
■エチルアルコール ８．０■ｄ１
−α−トコフェロール ０．１■香料
適 量■ポリオキシエチレ
ン（２０）硬化ヒマシ油 ０．３■グリセリン
７．０■１，３−ブチレングリコー
ル ４．０■Ｌ−アスコルビン酸りん酸マグネ
シウム３．Ｏ■パラオキシ安息酸メチル
０．２［相］クエン酸
０． ２■クエン酸ナトリウム １
．００精製氷を加えて全量を１００とする。Example-1 Lotion ■ Ethyl alcohol 8.0 ■ d1
-α-Tocopherol 0.1 ■Fragrance
Appropriate amount ■ Polyoxyethylene (20) hydrogenated castor oil 0.3 ■ Glycerin
7.0 ■ 1,3-butylene glycol 4.0 ■ Magnesium L-ascorbic acid phosphate 3. O Methyl paraoxybenzoate
0.2 [phase] citric acid
0. 2 ■ Sodium citrate 1
．． Add 0.00 purified ice to make the total volume 100.
■に■から■を溶解し、Ａとする。次ぎに、■から■を
０に溶解して、Ｂとする。ＢにＡを添加した後、Ｎｏ、
５ Ｃのろ紙でろ過する。Dissolve ■ from ■ in ■ to obtain A. Next, B is obtained by dissolving ■ to ■ to 0. After adding A to B, No.
5 Filter through C filter paper.
実施例−２クリーム
■スクワラン ５・ ０■セ
チルアルコール １．５■ポリオキ
シエチレン（２０）
ソルビタンモノステアレート ２． ０■ポリオキ
シエチレン（２０）
セチルエーテル １．５■ワセリン
３．５■ミリスチン酸
オクチルドデシル ５．０■ｄｌ−α−トコフェ
ロール ０．５■１，３−ブチレングリコー
ル ６．０■Ｌ−アスコルビン酸りん酸マグネ
シウム３．０［相］クエン酸ナトリウム
０．５０パラオキシ安息香酸メチル
０．２■香料 適 量
０精製水を加えて全量を１００とする。Example-2 Cream ■ Squalane 5. 0 ■ Cetyl alcohol 1.5 ■ Polyoxyethylene (20) Sorbitan monostearate 2. 0 ■ Polyoxyethylene (20) Cetyl ether 1.5 ■ Vaseline
3.5 ■ Octyldodecyl myristate 5.0 ■ dl-α-tocopherol 0.5 ■ 1,3-butylene glycol 6.0 ■ L-ascorbic acid magnesium phosphate 3.0 [Phase] Sodium citrate
0.50 Methyl paraoxybenzoate
0.2 ■Fragrance Appropriate amount 0 Add purified water to make the total amount 100.
■から■を８０℃で溶解し、Ａとする。■から■及び［
相］を８０℃で溶解し、Ｂとする。ＡにＢを撹伴しなが
ら乳化し、７０℃で＠を添加して、３０℃まで撹伴しな
がら冷却する。Dissolve ① to ② at 80°C to obtain A. ■ to ■ and [
Phase] was dissolved at 80°C and designated as B. Emulsify A with B while stirring, add @ at 70°C, and cool to 30°C with stirring.
実施例−３パック
■カルボキシメチルセルロース １．５■１，
３−ブチレングリコール ５． ０■グリセリ
ン ７．０■エチルアルコ
ール ３．０■ポリオキシエチレン
（２０）
ラウリルエーテル ０．５■酢酸トコフエ
ロール ０． ２■Ｌ−アスコルビン
酸りん酸マグネシウム１．５■香料
適 量■精製水を加えて全量を１００と
する。Example - 3 pack ■ Carboxymethyl cellulose 1.5 ■ 1,
3-Butylene glycol 5. 0 ■ Glycerin 7.0 ■ Ethyl alcohol 3.0 ■ Polyoxyethylene (20) Lauryl ether 0.5 ■ Tocopherol acetate 0. 2■L-ascorbic acid magnesium phosphate 1.5■Fragrance
Appropriate amount ■ Add purified water to make the total volume 100.
■から■を■に６０℃で溶解し、■と■を添加して、３
０℃まで撹伴しながら冷却する。Dissolve ■ from ■ in ■ at 60℃, add ■ and ■, and
Cool with stirring to 0°C.
実施例−４乳 液
■スクワラン ３．０■ワセ
リン ２．０■マイク
ロクリスタリンワツクス １．０■ステアリルア
ルコール ０． ５■ｄ１〜α−トコフ
ェロール １・ Ｏ■ソルビタンセスキオレ
イン酸エステル １．５■ポリオキシエチレン（２０）
ソルビタンモノオレイン酸エステル ２． ０■グリ
セリン ５．０■Ｌ−アスコ
ルビン酸りん酸マグネシウム０． ５［相］パラオキシ
安怠香酸メチル ０． ２■香料
適 量＠精製水を加えて全量を
１００とする。Example-4 Emulsion ■ Squalane 3.0 ■ Vaseline 2.0 ■ Microcrystalline wax 1.0 ■ Stearyl alcohol 0. 5■d1~α-tocopherol 1. O■Sorbitan sesquioleate 1.5■Polyoxyethylene (20) Sorbitan monooleate 2. 0 ■ Glycerin 5.0 ■ Magnesium L-ascorbic acid phosphate 0. 5 [Phase] Methyl paraoxybenzoate 0. 2 ■Fragrance
Add an appropriate amount of purified water to make the total volume 100.
■から■を８０°Ｃで溶解し、Ａとする。■、［相］を
＠に８０℃で溶解してＢとする。ＡにＢを撹伴しながら
溶解し、７０℃で■を添加して、３０ ’Ｃまで撹伴し
ながら冷却する。Dissolve ① to ② at 80°C to obtain A. ■, [Phase] is dissolved in @ at 80°C to obtain B. Dissolve B in A with stirring, add ① at 70°C, and cool to 30°C with stirring.
本発明の化粧料は、Ｌ−アスコルビン酸りん酸マグネシ
ウムとビタミンＥ又はその誘導体を併用することにより
、皮膚透過性に優れ、しみ、色黒、そばかすを著しく改
善させ、美白効果が相乗的に増大し、さらに、安定性に
優れた化粧料である。By using magnesium L-ascorbic acid phosphate in combination with vitamin E or its derivatives, the cosmetic of the present invention has excellent skin permeability, significantly improves age spots, dark skin, and freckles, and synergistically increases the whitening effect. Furthermore, it is a cosmetic with excellent stability.
次ぎに、本発明の効果について、皮膚透過性試験、長期
連用試験、水系安定性試験での結果をしめす。Next, regarding the effects of the present invention, the results of a skin permeability test, a long-term use test, and an aqueous stability test are shown.
（皮膚透過性試験）
試験方法
ハートレイ系モルモット酸、（体重２００〜２５０ｇ）
の背部及び腹部を除毛した。５ｘ３ｃｍのリント布に試
料を１．５ｍｌのせ、両側腹部に１枚ずつ貼布した。貼
布は、リント布の上をサランラップで覆い、その上から
ビニールテープで固定し、閉塞貼布とした。(Skin permeability test) Test method Hartley guinea pig acid, (weight 200-250g)
Hair was removed from the back and abdomen. 1.5 ml of the sample was placed on a 5 x 3 cm lint cloth, and one piece was applied to each side of the abdomen. The patch was made by covering the lint cloth with Saran wrap and fixing it with vinyl tape from above.
１６時間貼布後、リント布を取り除き、皮膚を温水でよ
（洗浄した。その後、貼布部位をセロファンテープで数
回ストリッピングを行い、角層の＝８−
上部に残留する試料を取り除いた。モルモットを屠殺後
、両側腹部の皮膚を摘出した。湿重量を精秤し、細切し
た後同量のＰＨ４，７クエン酸−りん酸バッファーを加
え良く粉砕した後、８０００回転、１０分間遠心分離後
」二清をサンプリングし、高速液体クロマトグラフィー
（ＩＨＰＬｃ）にて透過量を測定した。After application for 16 hours, the lint cloth was removed and the skin was rinsed with warm water.The application site was then stripped several times with cellophane tape to remove the sample remaining on the upper part of the stratum corneum. After sacrificing the guinea pig, the skin on both sides of the abdomen was removed.The wet weight was accurately weighed, cut into small pieces, added with the same amount of PH4,7 citric acid-phosphate buffer, pulverized well, and centrifuged at 8000 rpm for 10 minutes. After separation, the two supernatants were sampled and the amount of permeation was measured using high performance liquid chromatography (IHPLc).
試料は、実施例−１の化粧水と下記の比較例−１から比
較例−３の化粧水について、実験を実施した。Experiments were conducted using the lotions of Example 1 and Comparative Examples 1 to 3 below as samples.
比較例−１化粧水
実施例−１のｄｉ−α−トコフェロールを除き他は同様
に調整した。Comparative Example 1 A lotion was prepared in the same manner as in Example 1 except for di-α-tocopherol.
比較例−２化粧水
実施例−１のＬ−アスコルビン酸りん酸マグネシウムを
、Ｌ−アスコルビン酸 ３．０として他は同様に調整し
た。Comparative Example 2 A lotion was prepared in the same manner as in Example 1 except that the magnesium L-ascorbic acid phosphate was changed to 3.0 L-ascorbic acid.
比較例−３化粧水
実施例−１のＬ−アスコルビン酸りん酸マグネシウムを
、Ｌ−アスコルビン酸ジパルミテート３．０として他は
同様に調整した。Comparative Example 3 A lotion was prepared in the same manner as in Example 1 except that L-ascorbyl magnesium phosphate was replaced with L-ascorbic acid dipalmitate 3.0.
試験結果
皮膚透過性試験結果を、表、１に示す。表、１から明ら
かな様に、本発明の化粧料は、比較例−１から比較例−
３までと比較して皮膚透過性に優れた新規化粧料である
。Test Results The skin permeability test results are shown in Table 1. As is clear from Table 1, the cosmetics of the present invention are from Comparative Example-1 to Comparative Example-
This is a new cosmetic with superior skin permeability compared to products up to 3.
なお、実施例−２、実施例−３、実施例−４についても
同様に優れた皮膚透過性の結果が得られた。In addition, similarly excellent skin permeability results were obtained for Examples 2, 3, and 4.
表、１
単位： （μｇ／ｇ、ｔｉＳＳｕｅ）
（長期連用試験）
試験方法
しみ、色黒、そばかすに悩む女性モニター６０名（１８
歳〜５２歳）を被験者として、１グル一プ２０名ずつ実
施例−２、比較例−４、比較例−５のクリームを３ケ月
間毎日使用させた。Table, 1 Unit: (μg/g, tiSSue) (Long-term continuous use test) Test method 60 female monitors (18
20 people per group were asked to use the creams of Example 2, Comparative Example 4, and Comparative Example 5 every day for 3 months.
３ケ月後の、しみ、色黒、そばかすの改善度合について
、他覚所見、自覚所見にて美白効果を判定した。Three months later, the whitening effect was determined based on objective and subjective findings regarding the degree of improvement in age spots, dark skin, and freckles.
試料は、実施例−２のクリームと下記の比較例−４、比
較例−５のクリームについて試験を実施した。As samples, the cream of Example 2 and the creams of Comparative Example 4 and Comparative Example 5 below were tested.
試験結果
°長期連用試験結果を表、２に示す。表、２から明らか
な様に、本発明の化粧料は、比較例−４と比較例−５と
比較して美白効果に優れた新規化粧料である。Test Results ° The long-term continuous use test results are shown in Table 2. As is clear from Table 2, the cosmetic of the present invention is a novel cosmetic with superior whitening effect compared to Comparative Example-4 and Comparative Example-5.
なお、実施例−１、実施例−３、実施例−４についても
同様に優れた美白効果の結果が得られた。In addition, similarly excellent whitening effect results were obtained for Example-1, Example-3, and Example-4.
表、２
（以下余白）
（水系安定性試験）
試験方法
実施例−１、比較例−１１、比較例−２の化粧水につい
て、温度４０℃、湿度７０％の条件下で安定性を試験し
た。安定性は、アスルビン酸及びアスコルビン酸誘導体
の残存率を測定した。Table 2 (blank below) (Aqueous stability test) The stability of the lotions of Test Method Example-1, Comparative Example-11, and Comparative Example-2 was tested under conditions of a temperature of 40°C and a humidity of 70%. . Stability was determined by measuring the residual rate of ascorbic acid and ascorbic acid derivatives.
試験結果
水系安定性試験結果を、表６３に示す。表、３より本発
明の化粧料は安定性に優れた新規化粧料である。Test Results The results of the aqueous stability test are shown in Table 63. From Table 3, the cosmetic of the present invention is a novel cosmetic with excellent stability.
なお、実施例−２、実施例−３、実施例−４についても
同様に優れた水系安定性の結果が得られた。In addition, similarly excellent aqueous stability results were obtained for Example-2, Example-3, and Example-4.
（以下余白） 表、３ 単位二％ 以 上 特許出願人 有限会社 野々川商事(Margin below) Table, 3 unit 2% that's all Patent applicant: Nonokawa Shoji Ltd.
Claims (3)
ミンＥ又はその誘導体の一種または二種以上を含有する
ことを特徴とする化粧料。(1) A cosmetic containing one or more of magnesium L-ascorbic acid phosphate and vitamin E or a derivative thereof.
０１〜５．０重量％含有せられてなる特許請求の範囲第
１項記載の美白化粧料。(2) Magnesium L-ascorbic acid phosphate contains 0.
The whitening cosmetic composition according to claim 1, wherein the whitening cosmetic composition contains 01 to 5.0% by weight.
ル、β−トコフェロール、γ−トコフェロール、δ−ト
コフェロール、酢酸トコフェロール、又はニコチン酸ト
コフェロールの中より選ばれ、その含有量が０．００１
〜２．０重量％含有せられてなる特許請求の範囲第１項
記載の美白化粧料。(3) Vitamin E or a derivative thereof is selected from α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, tocopherol acetate, or tocopherol nicotinate, and the content thereof is 0.001
2. The whitening cosmetic according to claim 1, which contains up to 2.0% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63109756A JP2663136B2 (en) | 1988-05-02 | 1988-05-02 | Whitening cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63109756A JP2663136B2 (en) | 1988-05-02 | 1988-05-02 | Whitening cosmetics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01283208A true JPH01283208A (en) | 1989-11-14 |
| JP2663136B2 JP2663136B2 (en) | 1997-10-15 |
Family
ID=14518446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63109756A Expired - Lifetime JP2663136B2 (en) | 1988-05-02 | 1988-05-02 | Whitening cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2663136B2 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08333260A (en) * | 1995-06-06 | 1996-12-17 | Kaminomoto Honpo:Kk | Skin preparation for external use |
| EP0964047A1 (en) * | 1998-06-01 | 1999-12-15 | Johnson & Johnson Consumer Companies, Inc. | Anti-oxidant system |
| US6017520A (en) * | 1991-10-23 | 2000-01-25 | Block Drug Company, Inc. | Penetration enhancement of topically applied therapeutic formulations |
| JP2001089357A (en) * | 1999-09-24 | 2001-04-03 | Alron Japan Inc | Method for releasing l-ascorbic acid, l-ascorbic acid derivative and/or l-ascorbic acid-containing extract to dermic layer of skin and composition therefor |
| CN1069904C (en) * | 1997-06-04 | 2001-08-22 | 株式会社太平洋 | Water stable L-ascorbic acid derivative and its preparation method, and beauty composition containing same for making face white-skinned |
| WO2007108438A1 (en) * | 2006-03-20 | 2007-09-27 | Rohto Pharmaceutical Co., Ltd. | External composition for promoting of glutathione production and relevant method |
| JP2007284430A (en) * | 2006-03-20 | 2007-11-01 | Rohto Pharmaceut Co Ltd | Glutathione production promoting agent |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5965007A (en) * | 1982-10-05 | 1984-04-13 | Nisshin Oil Mills Ltd:The | Oily beautifying and whitening cosmetic |
| JPS6078913A (en) * | 1983-10-06 | 1985-05-04 | Shiseido Co Ltd | Cosmetic |
| JPS63284116A (en) * | 1987-05-14 | 1988-11-21 | Pola Chem Ind Inc | External preparation for skin |
| JPS6483010A (en) * | 1987-09-25 | 1989-03-28 | Sansho Seiyaku Kk | Melanization inhibitory drug for external use |
-
1988
- 1988-05-02 JP JP63109756A patent/JP2663136B2/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5965007A (en) * | 1982-10-05 | 1984-04-13 | Nisshin Oil Mills Ltd:The | Oily beautifying and whitening cosmetic |
| JPS6078913A (en) * | 1983-10-06 | 1985-05-04 | Shiseido Co Ltd | Cosmetic |
| JPS63284116A (en) * | 1987-05-14 | 1988-11-21 | Pola Chem Ind Inc | External preparation for skin |
| JPS6483010A (en) * | 1987-09-25 | 1989-03-28 | Sansho Seiyaku Kk | Melanization inhibitory drug for external use |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017520A (en) * | 1991-10-23 | 2000-01-25 | Block Drug Company, Inc. | Penetration enhancement of topically applied therapeutic formulations |
| JPH08333260A (en) * | 1995-06-06 | 1996-12-17 | Kaminomoto Honpo:Kk | Skin preparation for external use |
| CN1069904C (en) * | 1997-06-04 | 2001-08-22 | 株式会社太平洋 | Water stable L-ascorbic acid derivative and its preparation method, and beauty composition containing same for making face white-skinned |
| EP0964047A1 (en) * | 1998-06-01 | 1999-12-15 | Johnson & Johnson Consumer Companies, Inc. | Anti-oxidant system |
| JP2001089357A (en) * | 1999-09-24 | 2001-04-03 | Alron Japan Inc | Method for releasing l-ascorbic acid, l-ascorbic acid derivative and/or l-ascorbic acid-containing extract to dermic layer of skin and composition therefor |
| WO2007108438A1 (en) * | 2006-03-20 | 2007-09-27 | Rohto Pharmaceutical Co., Ltd. | External composition for promoting of glutathione production and relevant method |
| JP2007284430A (en) * | 2006-03-20 | 2007-11-01 | Rohto Pharmaceut Co Ltd | Glutathione production promoting agent |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2663136B2 (en) | 1997-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2565513B2 (en) | Topical drug for suppressing melanin production | |
| JPH06336419A (en) | External agent for skin | |
| KR102301123B1 (en) | Cosmetic composition comprising retiniol steblized by mixed antioxidant | |
| JP2005120023A (en) | Skin care preparation | |
| JP2003267822A (en) | Skin care preparation | |
| JPH01283208A (en) | Beautifying cosmetic | |
| JPH03275613A (en) | Skin external agent | |
| JPH0533683B2 (en) | ||
| JPH07101844A (en) | Multilayered emulsion | |
| JP2881333B2 (en) | Whitening cosmetics | |
| JPH0867621A (en) | Skin activator having glycosaminoglycan production-accelerating action | |
| JP2552298B2 (en) | Beautiful skin cosmetics | |
| JP2676049B2 (en) | Skin cosmetics | |
| JP2565516B2 (en) | Topical skin | |
| JP5000964B2 (en) | Testosterone 5α-reductase activity inhibitor, androgen receptor antagonist, use thereof, and method for suppressing androgen activity expression | |
| JP2002370962A (en) | Bleaching preparation and cosmetic for preventing and improving aging of skin | |
| JPS61176510A (en) | Skin-beautifying cosmetic | |
| JPH09291021A (en) | Beautifying and whitening cosmetic | |
| JPH1036246A (en) | Suppressant for melanogenesis and preparation for external use for skin | |
| JPH07258063A (en) | External preparation for skin | |
| JP2556730B2 (en) | Skin cosmetics | |
| JPH0692833A (en) | Skin external agent | |
| JPS61194008A (en) | Cosmetic | |
| EP0445735A1 (en) | Melanogenesis-inhibiting endermic preparation | |
| JP2007022960A (en) | Melanogenesis inhibitor and bleaching cosmetic |